cetuximab

all catalysts(0)

nothing on the calendar yet

News(5)

• ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
  Incyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.
  fiercebiotech · 4d ago
• AstraZeneca scores in lung cancer; Sandoz inks a China deal
  A combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.
  biopharma_dive · 2mo ago
• Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
  The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
  biospace · 2mo ago
• Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD
  Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.
  onclive · 5mo ago
• Fierce Biotech Fundraising Tracker '26: Nouscom nabs $135M series D; Estuary channels $93M series A
  The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.
  fiercebiotech · 10mo ago